Karyopharm Announces Initiation of a Phase 1 Study of Decitabine (Dacogen(R)) and Selinexor (KPT-330) in Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Apr 15, 3:15PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in combination with the DNA methylation inhibitor decitabine (Dacogen) in patients with relapsed or refractory acute myeloid leukemia (AML) and in patients age greater-than or equal to60 years with newly diagnosed AML. The study is being conducted at The Ohio State University Comprehensive Cancer Center under the direction of principal investigator Ramiro Garzon, MD, Associate Professor.
Karyopharm elects Chris Primiano as VP
M2 - Fri Apr 11, 7:31AM CDT
US-based pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) announced on Thursday that it has hired Christopher B. Primiano as its vice president, general counsel and secretary.
Karyopharm Appoints Chris Primiano as General Counsel
GlobeNewswire - Thu Apr 10, 3:35PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the appointment of Christopher B. Primiano as Vice President, General Counsel and Secretary.
Karyopharm Therapeutics signs preferred provider agreement with Clinipace Worldwide
M2 - Thu Apr 10, 5:19AM CDT
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) revealed on Wednesday the execution of a preferred provider agreement to manage several clinical programmes, including oncology, wound healing and other diseases in partnership with Clinipace Worldwide .
Karyopharm Therapeutics Inc. Enters into Preferred Provider Agreement with Clinipace Worldwide
Business Wire - Wed Apr 09, 9:00AM CDT
Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases.
Karyopharm Therapeutics to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 08, 12:26PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Michael Kauffman, Chief Executive Officer, is scheduled to present a company overview at the 13 Annual Needham Healthcare Conference. The conference is being held at The Westin Grand Central Hotel in New York City. The presentation is scheduled for Wednesday, April 9, 2014 at 8:00 am EDT.
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Karyopharm Therapeutics, Inc. (KPTI) Catches Eye: Stock Jumps 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:44AM CST
Karyopharm Therapeutics, Inc. was a big mover last session, as the company saw its shares surge 14% on the day
Karyopharm Therapeutics Reports 2013 Year-End Financial Results and Provides Update on Clinical Development Plans
GlobeNewswire - Wed Mar 05, 5:30AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, reported financial results for the year ended December 31, 2013, and also provided an update on its clinical development plans.
Karyopharm Therapeutics Announces Initiation of an Investigator Sponsored Phase 1 Dose Escalation Study of Its Lead Drug Candidate Selinexor (KPT-330) in Singapore
GlobeNewswire - Thu Feb 27, 8:53AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 study of oral Selinexor in Asian patients with advanced or metastatic solid tumors. Selinexor (KPT-330), is a first-in-class, oral Selective Inhibitors of Nuclear Export (SINE) compound that covalently inhibits exportin-1 (XPO1/CRM1), which leads to the accumulation of tumor suppressor proteins in the cell nucleus and the selective induction of apoptosis in cancer cells. This study is designed to determine the recommended Phase 2 dose and assess the safety and preliminary evidence of anti-cancer activity in Asian patients. The study is being conducted by Drs. David Tan and Goh Boon Cher at the National University Cancer Institute, Singapore (NCIS)/National University Hospital (NUH) in Singapore. Dr. Tan is a consultant medical oncologist at the Department of Haematology-Oncology and Assistant Professor at the Yong Loo Lin School of Medicine, National University of Singapore (NUS). Dr. Goh is Head of the Department of Haematology-Oncology and Deputy Director of the Cancer Science Institute of Singapore at the National University of Singapore.
Karyopharm Therapeutics Announces Nine Presentations on its Selective Inhibitors of Nuclear Export (SINE) Compounds and PAK4 Inhibitors at the American Association of Cancer Research (AACR) Meeting
GlobeNewswire - Wed Feb 26, 3:09PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the presentation of seven posters covering its Selective Inhibitors of Nuclear Export (SINE) compounds and two posters covering its PAK4 inhibitors at the American Association of Cancer Research (AACR) meeting being held April 5-9, 2014 in San Diego, CA. Karyopharm's lead drug candidate, Selinexor (KPT-330), is a first-in-class, oral SINE compound that is undergoing Phase 1 studies in patients with advanced hematologic malignancies, solid tumors, and sarcomas. Karyopharm's allosteric PAK4 inhibitors are in preclinical development.
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:39AM CST
BioCryst Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 11% on the day.
Karyopharm Therapeutics to Present at Upcoming Healthcare Conferences in February
GlobeNewswire - Thu Feb 06, 7:30AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Michael Kauffman, Chief Executive Officer, is scheduled to present at the following conferences in February:
Karyopharm Therapeutics Inc. [KPTI] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Feb 05, 9:00AM CST
What:
Will Karyopharm (KPTI) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 5:57AM CST
Will Karyopharm (KPTI) Continue to Surge Higher?
This Week in Biotech: Clinical Success, Plus Wheeling and Dealing
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 25, 11:13AM CST
I don't know about you, but to me, between the J.P. Morgan Healthcare Conference two weeks ago and a flurry of earnings and trial data, it seems like an exceptionally furious start to the year for biotech stocks. This marks our third week in a row...
Why Karyopharm Therapeutics, Inc. Shares Vaulted Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 3:13PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Karyopharm Therapeutics , a clinical-stage...
Karyopharm Therapeutics Presents Clinical Data on Selinexor (KPT-330) in Colorectal Cancer From Ongoing Phase 1 Study and Preclinical Data on Novel PAK4 Inhibitors at American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium
GlobeNewswire - Wed Jan 22, 7:30AM CST
- Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients -
Karyopharm Therapeutics Announces Data Presentations at American Society of Clinical Oncology Annual Gastrointestinal Cancers Symposium
GlobeNewswire - Tue Jan 14, 7:30AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the presentation of two posters at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal (GI) Cancers Symposium being held January 16-18, 2014 in San Francisco, CA. The posters focus on the potential in GI cancers of lead candidate Selinexor (KPT-330) as well as novel PAK4 inhibitors.
Karyopharm Therapeutics awarded grant from National Multiple Sclerosis Society to further develop SINE compounds
M2 - Thu Jan 09, 4:33AM CST
Karyopharm Therapeutics Inc (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced on Wednesday the award of a grant from the National Multiple Sclerosis (MS) Society through its affiliate, Fast Forward, to support research on the potential of Selective Inhibitors of Nuclear Export (SINE) compounds in inflammatory models of disease, including Multiple Sclerosis (MS).